TaoWeave, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TaoWeave, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $331.0K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $911.0K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.55M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.72M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $8.05M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $5.40M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $4.96M | May 15, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.36M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($4.04M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($4.38M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($21.94M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($9.05M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($7.42M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($7.76M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($7.17M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $5.79M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($3.53M) | Mar 7, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.96M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($4.20M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($4.50M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($21.99M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($11.79M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($10.06M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($7.57M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($6.74M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($2.37M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($2.09M) | Mar 7, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.0K | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $155.0K | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $20.0K | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $1.70M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $2.91M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $3.71M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $2.02M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $921.0K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $1.15M | Mar 8, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.02M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($3.41M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($2.99M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($5.93M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($7.73M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($6.57M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($3.25M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($1.16M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $1.61M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $183.0K | Mar 7, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $0 | Mar 19, 2024 |
| FY2023 | Dec 31, 2022 | $11.0K | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $50.0K | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $38.0K | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $45.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $335.0K | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $133.0K | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $382.0K | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $1.25M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $2.18M | Mar 17, 2016 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.22M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $5.28M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $6.93M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $5.66M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $28.61M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $29.14M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $34.91M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $7.96M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $15.42M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $16.50M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $1.27M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $1.42M | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $2.04M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $3.11M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $7.09M | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | $13.12M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $1.13M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $3.16M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | $12.57M | Mar 7, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.03M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.00M | Mar 20, 2026 |
| FY2025 | Dec 31, 2023 | $5.50M | Mar 20, 2026 |
| FY2024 | Dec 31, 2022 | $3.62M | Mar 18, 2025 |
| FY2023 | Dec 31, 2021 | $25.50M | Mar 19, 2024 |
| FY2022 | Dec 31, 2020 | $22.06M | Mar 21, 2023 |
| FY2021 | Dec 31, 2019 | $21.79M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $6.83M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $12.26M | May 15, 2020 |
| FY2018 | Dec 31, 2016 | $3.93M | Mar 8, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 18, 2025 |
| FY2024 | Dec 31, 2023 | $0 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | $0 | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | $7.37M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | $7.37M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | $7.91M | Mar 29, 2022 |
| FY2020 | Dec 31, 2018 | $2.80M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $7.75M | May 15, 2020 |
| FY2017 | Dec 31, 2016 | $9.23M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $9.83M | Mar 31, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($238.63M) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | ($232.27M) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | ($228.23M) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | ($223.85M) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | ($201.91M) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | ($192.86M) | Mar 29, 2022 |
| FY2020 | Dec 31, 2019 | ($185.43M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($177.67M) | May 15, 2020 |
| FY2018 | Dec 31, 2017 | ($170.51M) | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | ($176.29M) | Mar 7, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | $4.97M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | $5.99M | Mar 18, 2025 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $2.42M | Mar 30, 2021 |
| FY2020 | Dec 31, 2019 | $5.51M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $0 | May 15, 2020 |
| FY2018 | Dec 31, 2017 | $1.56M | Mar 8, 2019 |
| FY2017 | Jun 30, 2017 | $11.50M | Mar 7, 2018 |
| FY2017 | Dec 31, 2016 | $10.66M | Mar 7, 2018 |
| FY2016 | Dec 31, 2015 | $10.99M | Mar 31, 2017 |
| FY2015 | Dec 31, 2014 | $11.19M | Mar 17, 2016 |
| FY2014 | Dec 31, 2013 | $11.19M | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $11.03M | Mar 6, 2014 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (2) | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | (15) | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | (18) | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 29, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 7, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 17, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 0 | Mar 19, 2024 |
| FY2023 | Dec 31, 2022 | (10) | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | (5) | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | (1) | Mar 29, 2022 |
| FY2018 | Dec 31, 2018 | 0 | Mar 8, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 7, 2018 |
| FY2015 | Dec 31, 2015 | 0 | Mar 17, 2016 |
| FY2015 | Dec 31, 2014 | 0 | Mar 17, 2016 |
| FY2014 | Dec 31, 2013 | 0 | Mar 5, 2015 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.33M | Mar 20, 2026 |
| FY2025 | Dec 31, 2024 | 1.14M | Mar 20, 2026 |
| FY2024 | Dec 31, 2023 | 573,455 | Mar 18, 2025 |
| FY2023 | Dec 31, 2022 | 2.06M | Mar 19, 2024 |
| FY2022 | Dec 31, 2021 | 2.05M | Mar 21, 2023 |
| FY2021 | Dec 31, 2020 | 7.75M | Mar 29, 2022 |
| FY2021 | Dec 31, 2019 | 5.16M | Mar 29, 2022 |
| FY2019 | Dec 31, 2018 | 4.98M | May 15, 2020 |
| FY2018 | Dec 31, 2017 | 44.51M | Mar 8, 2019 |
| FY2017 | Dec 31, 2016 | 36.46M | Mar 7, 2018 |